Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders


Sector: Healthcare | Sub-Sector: Drug Manufacturers - Major
Alternate Symbol(s):  BIOYF

Biosyent Inc is a life science company engaged in marketing of pharmaceutical products & manufacturing & marketing of non-chemical bio & health-friendly insecticides. It acquires or license products & commercializes technology to health & public safety.
Price: $7.02 | Change: $-0.05 | %Change: -0.71%
Volume: 13,141 | Day High/Low: 7.10/7.00 | 52 Week High/Low: 12.82/5.91
View modes: 
5 stars

More insider buying today

1154 shs, $8080.70  rate and reply
5 stars

RE:Management needs to do something

If RX ever goes after a big acquisition it will need to do a financing. This will involve an underwriter who would promote the stock with a research report and analyst coverage. RX may feel more
1 star

Management needs to do something

to promote this stock to raise the profile of the company  rate and reply
1 star

Under appreciated?

I think so.  For 5 years in a row, it's net income has kept on going up, yet, the stock price has been going down.  Why it is so is a mystery to me.  It could be that it is such more
5 stars

Insider buying

5000 shs. Today for $34,250  rate and reply
1 star

RE:TSX Ventre Snapshot.....

CORRECTION: " Venture"  rate and reply
1 star

TSX Ventre Snapshot.....

All time high ----> 3,370 (May,07,2007) 52wk high ----> 1,028 All time low ----> 537 (Today) Cheers!  rate and reply
0 stars

RE:Good buy

This looks like a valuable product for use in detecting bladder cancer.  The Photocure website contains a wealth of information on the product, including US sales info and growth (see more
0 stars

Good buy

So much potential just not enough long term buyers here...Donville needs to back it up for it to run again  rate and reply
4 stars

news  rate and reply
4 stars

RE:If I Was The CEO...

SEV down 20% since uplisting ($0.60 to $0.48)  rate and reply
3 stars

If I Was The CEO...

I would have gotten off of this exchange long ago, I would have issued more shares at over $10.00 a share as RX suffers with liquidity due the low float. At $10.00 another 5M shares would have more
1 star


.  rate and reply
5 stars

RE:RE:RE:cantor report

Cantor could look like fools for reducing the target price if RX ends up doing an acquisition in the near term....theinvestor22 wrote: International sales are at such an early stage that there' more
0 stars

RE:RE:cantor report

International sales are at such an early stage that there's never really been any visibility, so I'm not sure what CF is going on about there. Perhaps they just needed a reason or two ( more
3 stars

RE:cantor report

What a drop in the target price. Lack of visibility on international sales.  rate and reply
5 stars

cantor report

here you go: target moved to $9 which I think is fair; the days of straight up stock movement a la 2014 are over... this is going to take more
3.5 stars


Amazing isn't it. MPH has half the market cap of RX despite having OVER FOUR TIMES THE GROWTH RATE and similar sales and adjusted EBITDA for the first half of the year. MPH's adjusted more
5 stars


Not true fraudster..... RX ebitda $2.49 million for 6 months. MPH ebitda $1.4 million for 6 months MPH ebitda + stock-based compensation $2.15 million for 6 months. Sir_Holler wrote: RX and more
5 stars


Forward P/E of RX is 16.5x, for MPH it is 22x. So despite MPH having a better qtr than RX growth-wise it is all about future sales, earnings, cash flows......lscfa wrote: RX $6.50, target price $ more